Citius OncologyCTOR 10 Quick Ratio is 0.12 as of Mar. 2026, which is 9% above its 10-year median of 0.11. GuruFocus rates CTOR with a GF Score™ of 10/100. The stock has 2 warning signs investors should review. Among 997 Drug Manufacturers companies, Citius Oncology ranks worse than 96.49% on this metric.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Citius Oncology's quick ratio for the quarter that ended in Mar. 2026 was 0.12.
Citius Oncology has a quick ratio of 0.12. It indicates that the company cannot currently fully pay back its current liabilities.
The historical rank and industry rank for Citius Oncology's Quick Ratio or its related term are showing as below:
CTOR'
s Quick Ratio Range Over the Past 10 Years
Min: 0.02 Med: 0.11 Max: 0.46
Current: 0.12
During the past 4 years, Citius Oncology's highest Quick Ratio was 0.46. The lowest was 0.02. And the median was 0.11.
CTOR's Quick Ratio is ranked worse than 96.49% of 997
companies
in the Drug Manufacturers industry
Industry Median: 1.45
vs CTOR: 0.12
Citius Oncology (NAS:CTOR) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Citius Oncology Quick Ratio Related Terms
Citius Oncology Quick Ratio Historical Data
* Premium members only.
The historical data trend for Citius Oncology's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Citius Oncology's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Citius Oncology Quick Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Citius Oncology's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Citius Oncology's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Citius Oncology's Quick Ratio for the fiscal year that ended in Sep. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Citius Oncology (CTOR) has a Quick Ratio of 0.12 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Citius Oncology and its competitors. This is near median its historical median of 0.11. Over the past decade, Citius Oncology's Quick Ratio has ranged from 0.02 to 0.46. According to the industry distribution chart, Citius Oncology ranks #962 out of 997 companies in the Drug Manufacturers industry, placing it in the top 96.5%.
Is Citius Oncology's Quick Ratio too high?
Citius Oncology's current Quick Ratio of 0.12 is near median its 10-year median of 0.11. Over the past 10 years, this metric has ranged from a low of 0.02 to a high of 0.46. The Drug Manufacturers industry median Quick Ratio is 1.45. Citius Oncology's value of 0.12 is 91.7% below this industry median. Based on the distribution chart, Citius Oncology ranks #962 out of 997 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Citius Oncology has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Citius Oncology's Quick Ratio compare to INCR and BGM?
According to the Drug Manufacturers industry distribution chart, Citius Oncology ranks #962 out of 997 companies for Quick Ratio. This places Citius Oncology in the lower half of its industry. The industry median Quick Ratio is 1.45. Citius Oncology's value of 0.12 is 91.7% below this benchmark. Historically, Citius Oncology's own Quick Ratio has ranged from 0.02 to 0.46 over the past decade. While the company's 10-year median is 0.11 vs. the industry median of 1.45, Citius Oncology has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Drug Manufacturers company?
The median Quick Ratio among Drug Manufacturers companies is 1.45, based on 997 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Citius Oncology's current Quick Ratio of 0.12 is 91.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Citius Oncology and its competitors. For the Drug Manufacturers industry, the median Quick Ratio is 1.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Citius Oncology's current Quick Ratio is 0.12, which is near median its own 10-year median of 0.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Citius Oncology stock overvalued right now?
Citius Oncology (CTOR) has a current Quick Ratio of 0.12. The current Quick Ratio is 0.12, which is near median its 10-year median of 0.11 and 91.7% below the Drug Manufacturers industry median of 1.45. Citius Oncology's overall GF Score™ is 10/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Citius Oncology (CTOR), the current Quick Ratio is 0.12 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Citius Oncology Inc is a biopharmaceutical company focused on developing and commercializing targeted oncology therapies.The Company centers on achieving a market position by advancing therapies with reduced development and clinical risks, and competitive advantages supported by intellectual property and regulatory exclusivity protection. This includes new formulations of previously approved drugs with substantial existing safety and efficacy data or expanded indications for approved therapies. The company focused on key geographies and stakeholders, majorly on cancer centers and patients.
10GF Score
Get the complete analysis for CTOR
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CTOR has been successfully added to your 
